Deep 6 AI

Executive Summary

Deep 6 AI is a clinical trial acceleration company that uses artificial intelligence and natural language processing to analyze electronic health records and other clinical data. By rapidly identifying and recruiting eligible patients, the company addresses a critical bottleneck in drug development: patient enrollment, which accounts for a significant portion of trial delays. Founded in 2015 and based in Pasadena, California, Deep 6 AI has developed a platform that can process both structured and unstructured data, enabling it to match patients to trials in minutes rather than months. This capability is increasingly vital as the number of clinical trials grows and patient recruitment becomes more competitive. Deep 6 AI's technology offers a clear competitive advantage through its ability to interpret complex medical data and integrate with existing hospital systems. The market opportunity is substantial, given that over 80% of clinical trials fail to meet enrollment timelines, costing the industry billions annually. While the company has not publicly disclosed funding or valuation, its technology aligns with the broader shift toward AI-driven healthcare solutions. With growing regulatory acceptance and partnerships, Deep 6 AI is well-positioned to capture market share in the clinical trial acceleration space, though it faces competition from other AI platforms and traditional recruitment methods.

Upcoming Catalysts (preview)

• Q3 2026Series B Funding Announcement60% success
• Q4 2026Major Pharmaceutical Partnership50% success
• Q2 2026Expansion into Oncology Trial Recruitment70% success